20Jan 2017

NANOPARTICLES: NEOTERIC PLATFORM AGAINST MULTI DRUG RESISTANCE TUBERCULOSIS.

  • Department Of Pharmaceutics, DeccanSchool Of Pharmacy, Dar us salam, Aghapura, Nampally, Hyderabad Telangana, India.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Tuberculosis caused by Mycobacterium strains intracellular bacilli is a pernicious infection posing global menace to public health. It kills about 2 million people per year worldwide and has been declared as “Global emergency” by WHO. Nano particulate drug delivery systems are suitable for targeting chronic intracellular infections such as tuberculosis. Given the options for oral as well as parenteral therapy the very nature of the disease and its complex treatment urges one to emphasize on the oral route for controlled drug delivery. Treatment of drug susceptible TB continues for a period of 6 – 9 months, while Multi Drug Resistance TB requires rigorous treatment with second line anti-TB drugs that has many unacceptable systemic side effects. These arduous treatment regimens and lack of knowledge regarding the importance of completing the treatment course can cause non-adherence of patient to the medications that remains the most important reason for treatment failure. Targeted drug delivery in the form of nanoparticles holds significance in combating TB bacilli by prolonged and intracellular drug release. Pending are the discovery of more potent anti-tuberculosis drugs, nanotechnology based intermittent chemotherapy provides a novel and sound platform for an onslaught against tuberculosis. The current review discusses the traditional anti-TB drugs and the advantages of targeted delivery of nanoparticles over conventional treatment in terms of efficacy, reduced frequency of dosing, decreased duration of treatment regimens and reduced systemic toxicity.


  1. National Institute of Allergy and Infectious Disease NIAID. Available at https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-institute-allergy-infectious-diseases-niaid.
  2. World Health Organization (WHO) Report 2012. Global TB control. Available at http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf
  3. Russell DG, Barry CE 3rd, Flynn JA. Tuberculosis: what we don’t know can, and does, hurt us. Science. 2010;328(5980):852–856.
  4. Multi Drug-Resistant Tuberculosis (MDR_TB) 2015 Update WHO.Available at http://www.who.int/tb/challenges/mdr/mdr_tb_factsheet.pdf
  5. McCary E, Weinbaum CM, Barden CR, Onorato IM. The epidemiology of tuberculosis in the- United States, Clin Chest Med 1997;18:99-113
  6. Centre for disease control and prevention. Meeting the challenge of multi-resistant tuberculosis: Summary of a conference. MMWR 1992; 41:51-71.
  7. Kang HW, Weissleder R, Bogdanov A Jr. Targeting of M-PEG protected polyamino acid carrier to human E- selectin in vitro. Amino acid 2002; 23 (1-3); 301-308
 
  1. Langer R. Biomaterials in drug delivery and tissue engineering: one laboratory\'s experience. Acc Chem Res 2000; 33: 94-101.
  2. Kreuter J. Nanoparticles as drug delivery system. In: Nalwa HS, editor. Encyclopedia of Nanoscience and Nanotechnology. New York: American Science Publishers; 2004. p. 161-80.
  3. Herrero-Vanrell R, Rincón AC, Alonso M, Reboto V, Molina-Martinez IT, Rodríguez-Cabello JC. Self-assembled particles of an elastin-like polymer as vehicles for controlled drug release. J Controlled Release. 2005; 102:113–122.
  4. Gelperina, S., Kisich, K., Iseman, M. D. & Heifets, L. (2005). The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 172(12), 1487- 1490
  5. Ahmad, M. Maqbool,A. F. Raja Nanomedicine for tuberculosis: Insights from animal models International Journal of Nano Dimension Int.J.Nano Dim. 2(1): 67-84, Summer 2011
  6. Chen, R.K. McCulloch, B.N. Gray Synthesis of albumin-dextran sulfate microspheres possessing favorable loading and release characteristics for the anti-cancer drug doxorubicin. Control Rel., 31 (1) (1994), pp. 49–54
  7. Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges J Antimicrob Chemother. 2005 Apr;55(4):430-5. Epub 2005 Mar 10.
  8. Lisa Claire du Toit,Viness Pillay, and Michael Paul DanckwertsTuberculosis chemotherapy: current drug delivery approaches. Respiratory Research, BioMed central the open access publisher, Volume 7(1); 2006
  9. Mitchison D. Basic mechanism of chemotherapy. Chest, 1979; 76:771-781.
  10. Zhang Y. The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol, 2005; 45:529-564.
  11. Sagar R. Mudshinge, Amol B. Deore, Sachin Patil, Chetan M. BhalgatNanoparticles: Emerging carriers for drug delivery Saudi Pharmaceutical JournalVolume 19, Issue 3, July 2011, Pages 129–141
  12. Muller RH, Wallis KH. Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908. Int. J. Pharm. 1993; 89: 25-31.
  13. Bhadra D, Bhadra S, Jain P, Jain NK. Pegnology: a review of PEG-ylated systems. Pharmazie 2002; 57: 5-29. 3
  14. Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule technology: a review. Crit Rev Ther Drug Carrier Syst 2002; 19: 99-134.
  15. VJ Mohanraj and Y Chen, Nanoparticles – A Review, Tropical Journal of Pharmaceutical Research, June 2006; 5 (1): 561-573
  16. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J. Control. Rel. 1999; 57: 171-185.
  17. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Polymer Sci. 1997; 63: 125-132.
  18. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res. 1997; 14: 1431-1436.
  19. Lamprecht A, Ubrich N, Yamamoto H, Schäfer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel diseaseJ Pharmacol Exp Ther. 2001 Nov; 299(2):775-81.
  20. PandeyR, Zahoor A,Sharma S, Khuller GK.Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb) 2003; 83:373–378.
  21. Deol P, Khuller GK. Lung specific stealth liposomes; stability, biodistribution and toxicity of liposomal antituberculosis drugs in mice. Biochem Biophys Acta; 1997: 1334:161-172.
  22. Lehr, C. M. (2000), Lectin-mediated drug delivery: the second generation of bioadhesives. J Control Release,65, 19-29.
  23. Susmita Sarkar, Mavanur R. Suresh An Overview of Tuberculosis Chemotherapy – A Literature Review J Pharm Pharmaceut Sci (www.cspsCanada.org) 14(2) 148 - 161, 2011
  24. The lectin- cell interaction and its implications to intestinal lectin-mediated drug delivery. Gabor F, Bogner E, Weissenboeck A, Wirth M.
  25. Aulton M.E. (2002). Pharmaceutics-The of Doasge Form Design (pp. 463) Churchill Livingstone.
  26. Sam, E., Jeanjean, A. P., Maloteaux, J. M., Verbeke, N. (1995). Apomorphin pharmacokinetics in Parkinsonism after intranasal and subcutaneous application. European Journal of Drug metabolism and Pharmacokinetics, 20(1), 27-33.
  27. Pandey, R., Sharma, A., Zahoor, A., Sharma, S., Khuller, G. K. & Prasad, B. (2003), Poly (DL-lactide-co-glycolide) nanoparticle based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemothe,52, 981-986.
 
  1. Sung, J. C., Padilla, D. J., Garcia-Contreras, L., Verberkmoes, J. L., Durbin, D. & Peloquin, C. A. (2009), Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res,26, 18471855.
  2. Ohashi, K., Kabasawa, T., Ozeki, T. & Okada, H. (2009), One-step preparation of rifampicin/poly (lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray dryer for inhalation therapy of tuberculosis. J Control Release,135, 19-24.
  3. Sung, J. C., Garcia-Contreras, L., Verberkmoes, J. L., Peloquin, C. A., Elbert, K. J. & Hickey, A. J. (2009), Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob Agents Chemother,53, 1338-1343.
  4. Pandey, R. & Khuller, G. K. (2004), Subcutaneous nanoparticle based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother,54, 266-268.
  5. Anisimova YV, Gelperina SE, Peloquin CA,Heifets IB. nanoparticles as antituberculosis drugs carriers: effect on activity against m. tuberculosis in human monocyte-derived macrophages. Journal of Nanoparticle Research, 2000; 2: 165-171
  6. Oral PLG NP based ATD: Toxicology and chemotherapeutic implications. R. Panday, Sadhna Sharma and G K Khuller.

[Madiha Nooreen and Uzma Khan. (2017); NANOPARTICLES: NEOTERIC PLATFORM AGAINST MULTI DRUG RESISTANCE TUBERCULOSIS. Int. J. of Adv. Res. 5 (1). 582-593] (ISSN 2320-5407). www.journalijar.com


MADIHA NOOREEN
DECCAN SCHOOL OF PHARMACY

DOI:


Article DOI: 10.21474/IJAR01/2786       DOI URL: http://dx.doi.org/10.21474/IJAR01/2786


Share this article